Beam Therapeutics BEAM Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's accrued expenses?
- Beam Therapeutics (BEAM) reported accrued expenses of $39.29M in Q1 2026.
- How has Beam Therapeutics's accrued expenses changed year-over-year?
- Beam Therapeutics's accrued expenses increased by 30.0% year-over-year, from $30.23M to $39.29M.
- What is the long-term trend for Beam Therapeutics's accrued expenses?
- Over 3 years (2022 to 2025), Beam Therapeutics's accrued expenses has grown at a 4.8% compound annual growth rate (CAGR), from $48.06M to $55.27M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.